Switching Antifibrotic Agents in Idiopathic Pulmonary Fibrosis (IPF)

Source: BMC Pulmonary Medicine
Findings:  IPF patients who switched from one antifibrotic therapy to the alternative — whether from pirfenidone (Esbriet) to nintedanib (Ofev, Vargatef) or the other way around – had improved survival. This observation held true whether the reason for switch was disease progress or tolerance issues.
Design: Multi-center retrospective cohort study; 262 patients